Long-term safety study of Livmarli in ALGS or PFIC
Part of Digestive system, Genetic & congenital, Heart & circulation clinical trials.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC).
- Your doctor has prescribed Livmarli (maralixibat) for you.
- You have not taken Livmarli before in a clinical study or expanded access program.
- You have never had a biliary diversion surgery or a liver transplant.
- You have not taken any experimental drug in the last 30 days.
- You are willing to provide consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
This trial tests a medicine called maralixibat to see if it helps children with cystic fibrosis who have chronic constipation that doesn't improve with standard treatments. The goal is to improve bowel movements and quality of life.
Hear when a new Alagille Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.